Researchers say a new drug-delivery implant could help patients with hard-to-treat bladder cancer avoid losing their bladders — and stay cancer-free for years.
The experts agreed that perioperative approaches in muscle-invasive bladder cancer continue to evolve. Ongoing data will ...
The IMvigor010 trial showed that Signatera-guided treatment with Tecentriq improved disease-free survival and overall ...
TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...
According to researcher Anne Robertson, the bladder is not considered a particularly glamorous organ, despite hosting many of ...
The bladder cancer treatment landscape is rapidly evolving, particularly for patients who don’t respond to bacillus ...
Patients with initially low- or intermediate-risk primary tumors will often have a high-risk recurrence before progressing to more advanced disease, whereas primary high-risk tumors typically show ...
Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a ...
A dietary supplement meant to support normal bladder control has been recalled because it may be contaminated with bacteria. Purity Products has recalled MyBladder due to potential contamination with ...
Hosted on MSN
UroGen Pharma’s Phase 3 Study on UGN-103: A Potential Game-Changer in Bladder Cancer Treatment
Urogen Pharma ((URGN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...
Only a fraction of women with overactive bladder (OAB) receive effective treatment for this condition; inequities in access to OAB care must be understood. The objective of this study was to explore ...
Send this article to your social connections.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback